Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial
The effectiveness of cyclosporine in the treatment of psoriasis was a serendipitous finding by Mueller and Herrmann, 1 who included four patients with psoriatic arthritis and psoriasis in a study of therapy for rheumatoid arthritis. We confirmed this finding in a double-blind trial of the efficacy o...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1991-01, Vol.324 (5), p.277-284 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 284 |
|---|---|
| container_issue | 5 |
| container_start_page | 277 |
| container_title | The New England journal of medicine |
| container_volume | 324 |
| creator | Ellis, Charles N Fradin, Mark S Messana, Joseph M Brown, Marc D Siegel, Michael T Hartley, A. Howland Rocher, Leslie L Wheeler, Suzanne Hamilton, Ted A Parish, Thomas G Ellis-Madu, Mary Duell, Elizabeth Annesley, Thomas M Cooper, Kevin D Voorhees, John J |
| description | The effectiveness of cyclosporine in the treatment of psoriasis was a serendipitous finding by Mueller and Herrmann,
1
who included four patients with psoriatic arthritis and psoriasis in a study of therapy for rheumatoid arthritis. We confirmed this finding in a double-blind trial of the efficacy of cyclosporine for psoriasis.
2
The effective doses of cyclosporine administered to patients with psoriasis in these and other trials ranged from 1 to 15 mg per kilogram of body weight per day.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Because the reports were based mainly on studies of small numbers of patients, it has been difficult to determine the proper dose.
Therefore, . . . |
| doi_str_mv | 10.1056/NEJM199101313240501 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1983424082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1983424082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-55bf5deb0e882ccff3ce40a977f04b71cc68945431c44af0f76002c233f833723</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotVZ_gQgF0YusZnaSTXIspX5RtYd6XrJpAlv2y6Q99N-bsgU9iHMZmHlm5p2XkEug90B59vA-e30DpYACAqaMcgpHZAgcMWGMZsdkSGkqEyYUnpKzENY0BjA1IANQMkulGJLb6c5UbehaXzZ27Fo_XlT6a2uT5a6z40WIdR3KcE5OnK6CvTjkEfl8nC2nz8n84-llOpknBiVsEs4Lx1e2oFbK1Bjn0FhGtRLCUVYIMCaTinGGYBjTjjqRRYkmRXQSUaQ4Itf93s63UUXY5Ot265t4Mo-SkcUv5Z7CnjK-DcFbl3e-rLXf5UDzvTX5H9bEqavD7m1R29XPTO9F7N8c-joYXTmvG1OGX5hQnGU8cnc9V9chb-y6_vfqN3OYdRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983424082</pqid></control><display><type>article</type><title>Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial</title><source>MEDLINE</source><source>New England Journal of Medicine Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><creator>Ellis, Charles N ; Fradin, Mark S ; Messana, Joseph M ; Brown, Marc D ; Siegel, Michael T ; Hartley, A. Howland ; Rocher, Leslie L ; Wheeler, Suzanne ; Hamilton, Ted A ; Parish, Thomas G ; Ellis-Madu, Mary ; Duell, Elizabeth ; Annesley, Thomas M ; Cooper, Kevin D ; Voorhees, John J</creator><creatorcontrib>Ellis, Charles N ; Fradin, Mark S ; Messana, Joseph M ; Brown, Marc D ; Siegel, Michael T ; Hartley, A. Howland ; Rocher, Leslie L ; Wheeler, Suzanne ; Hamilton, Ted A ; Parish, Thomas G ; Ellis-Madu, Mary ; Duell, Elizabeth ; Annesley, Thomas M ; Cooper, Kevin D ; Voorhees, John J</creatorcontrib><description>The effectiveness of cyclosporine in the treatment of psoriasis was a serendipitous finding by Mueller and Herrmann,
1
who included four patients with psoriatic arthritis and psoriasis in a study of therapy for rheumatoid arthritis. We confirmed this finding in a double-blind trial of the efficacy of cyclosporine for psoriasis.
2
The effective doses of cyclosporine administered to patients with psoriasis in these and other trials ranged from 1 to 15 mg per kilogram of body weight per day.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Because the reports were based mainly on studies of small numbers of patients, it has been difficult to determine the proper dose.
Therefore, . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199101313240501</identifier><identifier>PMID: 1986287</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Administration, Oral ; Adult ; Aged ; Antigens ; Arthritis ; Bilirubin ; Biological and medical sciences ; Blood pressure ; Body weight ; Cholesterol ; Creatinine ; Cyclosporins ; Cyclosporins - administration & dosage ; Cyclosporins - adverse effects ; Cyclosporins - therapeutic use ; Dermatology ; Double-Blind Method ; Drug dosages ; Female ; Glomerular filtration rate ; Humans ; Hypersensitivity, Delayed - immunology ; Immunomodulators ; Kidney - drug effects ; Laboratories ; Male ; Medical sciences ; Middle Aged ; Oral administration ; Pharmacology. Drug treatments ; Psoriasis ; Psoriasis - drug therapy ; Serum levels ; Side effects ; Skin - immunology ; Skin tests ; Uric acid</subject><ispartof>The New England journal of medicine, 1991-01, Vol.324 (5), p.277-284</ispartof><rights>1991 INIST-CNRS</rights><rights>Copyright Massachusetts Medical Society Jan 31, 1991</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c381t-55bf5deb0e882ccff3ce40a977f04b71cc68945431c44af0f76002c233f833723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199101313240501$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1983424082?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19795465$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1986287$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ellis, Charles N</creatorcontrib><creatorcontrib>Fradin, Mark S</creatorcontrib><creatorcontrib>Messana, Joseph M</creatorcontrib><creatorcontrib>Brown, Marc D</creatorcontrib><creatorcontrib>Siegel, Michael T</creatorcontrib><creatorcontrib>Hartley, A. Howland</creatorcontrib><creatorcontrib>Rocher, Leslie L</creatorcontrib><creatorcontrib>Wheeler, Suzanne</creatorcontrib><creatorcontrib>Hamilton, Ted A</creatorcontrib><creatorcontrib>Parish, Thomas G</creatorcontrib><creatorcontrib>Ellis-Madu, Mary</creatorcontrib><creatorcontrib>Duell, Elizabeth</creatorcontrib><creatorcontrib>Annesley, Thomas M</creatorcontrib><creatorcontrib>Cooper, Kevin D</creatorcontrib><creatorcontrib>Voorhees, John J</creatorcontrib><title>Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The effectiveness of cyclosporine in the treatment of psoriasis was a serendipitous finding by Mueller and Herrmann,
1
who included four patients with psoriatic arthritis and psoriasis in a study of therapy for rheumatoid arthritis. We confirmed this finding in a double-blind trial of the efficacy of cyclosporine for psoriasis.
2
The effective doses of cyclosporine administered to patients with psoriasis in these and other trials ranged from 1 to 15 mg per kilogram of body weight per day.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Because the reports were based mainly on studies of small numbers of patients, it has been difficult to determine the proper dose.
Therefore, . . .</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Antigens</subject><subject>Arthritis</subject><subject>Bilirubin</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Body weight</subject><subject>Cholesterol</subject><subject>Creatinine</subject><subject>Cyclosporins</subject><subject>Cyclosporins - administration & dosage</subject><subject>Cyclosporins - adverse effects</subject><subject>Cyclosporins - therapeutic use</subject><subject>Dermatology</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Glomerular filtration rate</subject><subject>Humans</subject><subject>Hypersensitivity, Delayed - immunology</subject><subject>Immunomodulators</subject><subject>Kidney - drug effects</subject><subject>Laboratories</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Oral administration</subject><subject>Pharmacology. Drug treatments</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Serum levels</subject><subject>Side effects</subject><subject>Skin - immunology</subject><subject>Skin tests</subject><subject>Uric acid</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kE1LAzEQhoMotVZ_gQgF0YusZnaSTXIspX5RtYd6XrJpAlv2y6Q99N-bsgU9iHMZmHlm5p2XkEug90B59vA-e30DpYACAqaMcgpHZAgcMWGMZsdkSGkqEyYUnpKzENY0BjA1IANQMkulGJLb6c5UbehaXzZ27Fo_XlT6a2uT5a6z40WIdR3KcE5OnK6CvTjkEfl8nC2nz8n84-llOpknBiVsEs4Lx1e2oFbK1Bjn0FhGtRLCUVYIMCaTinGGYBjTjjqRRYkmRXQSUaQ4Itf93s63UUXY5Ot265t4Mo-SkcUv5Z7CnjK-DcFbl3e-rLXf5UDzvTX5H9bEqavD7m1R29XPTO9F7N8c-joYXTmvG1OGX5hQnGU8cnc9V9chb-y6_vfqN3OYdRw</recordid><startdate>19910131</startdate><enddate>19910131</enddate><creator>Ellis, Charles N</creator><creator>Fradin, Mark S</creator><creator>Messana, Joseph M</creator><creator>Brown, Marc D</creator><creator>Siegel, Michael T</creator><creator>Hartley, A. Howland</creator><creator>Rocher, Leslie L</creator><creator>Wheeler, Suzanne</creator><creator>Hamilton, Ted A</creator><creator>Parish, Thomas G</creator><creator>Ellis-Madu, Mary</creator><creator>Duell, Elizabeth</creator><creator>Annesley, Thomas M</creator><creator>Cooper, Kevin D</creator><creator>Voorhees, John J</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>19910131</creationdate><title>Cyclosporine for Plaque-Type Psoriasis</title><author>Ellis, Charles N ; Fradin, Mark S ; Messana, Joseph M ; Brown, Marc D ; Siegel, Michael T ; Hartley, A. Howland ; Rocher, Leslie L ; Wheeler, Suzanne ; Hamilton, Ted A ; Parish, Thomas G ; Ellis-Madu, Mary ; Duell, Elizabeth ; Annesley, Thomas M ; Cooper, Kevin D ; Voorhees, John J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-55bf5deb0e882ccff3ce40a977f04b71cc68945431c44af0f76002c233f833723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Antigens</topic><topic>Arthritis</topic><topic>Bilirubin</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Body weight</topic><topic>Cholesterol</topic><topic>Creatinine</topic><topic>Cyclosporins</topic><topic>Cyclosporins - administration & dosage</topic><topic>Cyclosporins - adverse effects</topic><topic>Cyclosporins - therapeutic use</topic><topic>Dermatology</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Glomerular filtration rate</topic><topic>Humans</topic><topic>Hypersensitivity, Delayed - immunology</topic><topic>Immunomodulators</topic><topic>Kidney - drug effects</topic><topic>Laboratories</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Oral administration</topic><topic>Pharmacology. Drug treatments</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Serum levels</topic><topic>Side effects</topic><topic>Skin - immunology</topic><topic>Skin tests</topic><topic>Uric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ellis, Charles N</creatorcontrib><creatorcontrib>Fradin, Mark S</creatorcontrib><creatorcontrib>Messana, Joseph M</creatorcontrib><creatorcontrib>Brown, Marc D</creatorcontrib><creatorcontrib>Siegel, Michael T</creatorcontrib><creatorcontrib>Hartley, A. Howland</creatorcontrib><creatorcontrib>Rocher, Leslie L</creatorcontrib><creatorcontrib>Wheeler, Suzanne</creatorcontrib><creatorcontrib>Hamilton, Ted A</creatorcontrib><creatorcontrib>Parish, Thomas G</creatorcontrib><creatorcontrib>Ellis-Madu, Mary</creatorcontrib><creatorcontrib>Duell, Elizabeth</creatorcontrib><creatorcontrib>Annesley, Thomas M</creatorcontrib><creatorcontrib>Cooper, Kevin D</creatorcontrib><creatorcontrib>Voorhees, John J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ellis, Charles N</au><au>Fradin, Mark S</au><au>Messana, Joseph M</au><au>Brown, Marc D</au><au>Siegel, Michael T</au><au>Hartley, A. Howland</au><au>Rocher, Leslie L</au><au>Wheeler, Suzanne</au><au>Hamilton, Ted A</au><au>Parish, Thomas G</au><au>Ellis-Madu, Mary</au><au>Duell, Elizabeth</au><au>Annesley, Thomas M</au><au>Cooper, Kevin D</au><au>Voorhees, John J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1991-01-31</date><risdate>1991</risdate><volume>324</volume><issue>5</issue><spage>277</spage><epage>284</epage><pages>277-284</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>The effectiveness of cyclosporine in the treatment of psoriasis was a serendipitous finding by Mueller and Herrmann,
1
who included four patients with psoriatic arthritis and psoriasis in a study of therapy for rheumatoid arthritis. We confirmed this finding in a double-blind trial of the efficacy of cyclosporine for psoriasis.
2
The effective doses of cyclosporine administered to patients with psoriasis in these and other trials ranged from 1 to 15 mg per kilogram of body weight per day.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Because the reports were based mainly on studies of small numbers of patients, it has been difficult to determine the proper dose.
Therefore, . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>1986287</pmid><doi>10.1056/NEJM199101313240501</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1991-01, Vol.324 (5), p.277-284 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_1983424082 |
| source | MEDLINE; New England Journal of Medicine Current; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland |
| subjects | Administration, Oral Adult Aged Antigens Arthritis Bilirubin Biological and medical sciences Blood pressure Body weight Cholesterol Creatinine Cyclosporins Cyclosporins - administration & dosage Cyclosporins - adverse effects Cyclosporins - therapeutic use Dermatology Double-Blind Method Drug dosages Female Glomerular filtration rate Humans Hypersensitivity, Delayed - immunology Immunomodulators Kidney - drug effects Laboratories Male Medical sciences Middle Aged Oral administration Pharmacology. Drug treatments Psoriasis Psoriasis - drug therapy Serum levels Side effects Skin - immunology Skin tests Uric acid |
| title | Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T08%3A55%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cyclosporine%20for%20Plaque-Type%20Psoriasis:%20Results%20of%20a%20Multidose,%20Double-Blind%20Trial&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Ellis,%20Charles%20N&rft.date=1991-01-31&rft.volume=324&rft.issue=5&rft.spage=277&rft.epage=284&rft.pages=277-284&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199101313240501&rft_dat=%3Cproquest_cross%3E1983424082%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983424082&rft_id=info:pmid/1986287&rfr_iscdi=true |